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ABSTRACT
Introduction CD248 (endosialin) is a stromal cell
marker expressed on ﬁbroblasts and pericytes. During
liver injury, myoﬁbroblasts are the main source of ﬁbrotic
matrix.
Objective To determine the role of CD248 in the
development of liver ﬁbrosis in the rodent and human
setting.
Design CD248 expression was studied by
immunostaining and quantitative PCR in both normal
and diseased human and murine liver tissue and isolated
hepatic stellate cells (HSCs). Hepatic ﬁbrosis was induced
in CD248−/− and wild-type controls with carbon
tetrachloride (CCl4) treatment.
Results Expression of CD248 was seen in normal liver
of humans and mice but was signiﬁcantly increased in
liver injury using both immunostaining and gene
expression assays. CD248 was co-expressed with a
range of ﬁbroblast/HSC markers including desmin,
vimentin and α-smooth muscle actin (α-SMA) in murine
and human liver sections. CD248 expression was
restricted to isolated primary murine and human HSC.
Collagen deposition and α-SMA expression, but not
inﬂammation and neoangiogenesis, was reduced in
CD248−/− mice compared with wild-type mice after CCl4
treatment. Isolated HSC from wild-type and CD248−/−
mice expressed platelet-derived growth factor receptor α
(PDGFR-α) and PDGFR-β at similar levels. As expected,
PDGF-BB stimulation induced proliferation of wild-type
HSC, whereas CD248−/− HSC did not demonstrate a
proliferative response to PDGF-BB. Abrogated PDGF
signalling in CD248−/− HSC was conﬁrmed by
signiﬁcantly reduced c-fos expression in CD248−/−
HSC compared with wild-type HSC.
Conclusions Our data show that deletion of CD248
reduces susceptibility to liver ﬁbrosis via an effect on
PDGF signalling, making it an attractive clinical target
for the treatment of liver injury.
INTRODUCTION
Progressive liver ﬁbrosis represents one of the major
consequences of chronic hepatic injury and is asso-
ciated with the activation of hepatic stellate cells
(HSCs) from a quiescent state into proliferative,
α-smooth muscle actin (α-SMA)-positive myoﬁbro-
blasts that produce a variety of extracellular matrix
(ECM) proteins.1 Identiﬁcation of mechanisms
central to the development of liver ﬁbrosis offers the
potential to target these molecules in the develop-
ment of antiﬁbrotic therapies.
CD248, also known as endosialin and tumour
endothelial marker 1, is a trans-membrane glyco-
protein initially believed to be expressed on endo-
thelial cells of different cancers including colon2
and brain.3 Its expression was subsequently shown
to be on perivascular NG2+ cells (pericytes) in the
tumour vasculature as well as on interstitial ﬁbro-
blasts4 and mesenchymal stem cells.5 Outside the
setting of cancer, CD248 appears to be develop-
mentally regulated with expression occurring early
during embryonic development,6 although it is not
essential for development as CD248-deﬁcient mice
are viable and fertile.7
CD248 expression largely disappears in the adult,
only reappearing during infection, tissue repair6 and
cancer.5 In the setting of cancer, CD248 expressing
stromal cells interact with potential ligands includ-
ing ﬁbronectin and collagen types I and IV and
exhibit enhanced adhesion and migration through
Matrigel supporting a role for CD248 in tumour
progression and invasion.8 A role for CD248 has
Signiﬁcance of this study
What is already known on this subject?
▸ Fibrosis key is a challenge in hepatology for
which new therapies are needed.
▸ Activation of hepatic stellate cells is critical to
the development of liver ﬁbrosis.
What are the new ﬁndings?
▸ CD248 is upregulated at gene and protein level
in both murine and human liver ﬁbrosis.
▸ Deletion of CD248 reduces development of liver
ﬁbrosis during chronic liver injury.
▸ CD248 effect is mediated through abrogated
platelet-derived growth factor signalling in
hepatic stellate cells.
How might it impact on clinical practice in
the foreseeable future?
▸ CD248 is an attractive target for antiﬁbrotic
drugs and merits consideration in clinical trials.
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been conﬁrmed in the setting of chronic kidney disease, where
CD248 is expressed on myoﬁbroblasts and has been demon-
strated to serve as marker for both the extent of renal ﬁbrosis and
disease outcome.9
The role of CD248 in liver ﬁbrosis has not yet been estab-
lished, but given its potential role in other ﬁbrotic diseases, we
sought to evaluate the function of CD248 in chronic liver
injury. Herein, we demonstrate that CD248 expression is upre-
gulated in hepatic ﬁbrosis where its expression is conﬁned to
HSCs and myoﬁbroblasts. Moreover, we illustrate that genetic
deletion of CD248 protects against the development of ﬁbrosis,
despite similar levels of liver injury, inﬂammation and neoangio-
genesis, in a murine model of chronic hepatocellular injury by
interfering with platelet-derived growth factor (PDGF) signal-
ling, and therefore represents a novel target for therapeutic
intervention in ﬁbrotic liver injury.
MATERIALS AND METHODS
Human liver tissue
Tissue was obtained with ethical approval and consent from the
liver unit at Queen Elizabeth Hospital Birmingham, UK.
Explanted human liver specimens were obtained from patients
with alcoholic liver disease, non-alcoholic steatohepatitis,
primary biliary cirrhosis and autoimmune hepatitis. Normal
donor liver surplus to surgical requirements or as a by-product
of surgical resection served as normal controls.
Mice
C57Bl/6 CD248−/−7 mice were a gift from David Huso ( Johns
Hopkins University, USA). Wild-type C57Bl/6 (CD248+/+, here-
after termed WT) were purchased from Harlan Laboratories,
UK. Six-week-old to 10-week-old CD248−/− and WT mice
received twice-weekly intraperitoneal carbon tetrachloride
(CCl4) injections (0.25 mL/kg (Sigma)) for 8 or 12 weeks to
induce chronic liver injury and were sacriﬁced 2 days after the
last dose. Mineral oil was used as vehicle. In some instances,
mice received CCl4 for 8 weeks and were sacriﬁced 4 weeks
after administration of last dose (resubmission group). All
animal procedures were conducted in accordance with UK laws
with the approval of the Home Ofﬁce and local ethics commit-
tees (PPL 40/3201). To assess liver function, alanine aminotrans-
ferase (ALT) activity was measured in serum samples at the
clinical biochemistry laboratory of the Women’s Hospital
Birmingham (Birmingham, UK).
Isolation of primary human and murine liver-derived cells
Primary human and mouse HSCs were isolated and grown as
described previously.10 11 Human HSCs were isolated from
uninvolved liver tissue of patients undergoing surgical resection
for primary or secondary liver malignancy. Murine HSCs were
isolated from normal livers. HSCs were isolated by pronase/col-
lagenase digestion and separated by buoyancy centrifugation.
HSC activated spontaneously in culture over 10 days with loss
of retinoic acid, phenotypic changes and up-regulation of
α-SMA. HSC cultures were in some instances stimulated with
PDGF-BB (1–100 ng/mL; Peprotech, London, UK) for 24 h.
Isolation of biliary epithelial cells, endothelial cell, hepatocytes
and liver myoﬁbroblasts was performed using explanted end-
stage diseased liver tissue as described previously.10 12
Light microscopy and immunohistochemistry
Parafﬁn-embedded mouse liver tissue cut to 3 μm thickness was
stained with H&E using standard protocols. For immunohisto-
chemical studies, parafﬁn-embedded mouse liver sections were
incubated with optimally diluted rabbit antimouse vimentin,
rabbit antimouse desmin, rabbit antimouse F4/80 (all Abcam,
Cambridge, UK) or rat antimouse CD45 (eBioscience, Hatﬁeld,
UK) using a Dako Autostainer. Staining was detected with
immPRESS antirabbit secondary antibody and visualised in
NovaRED chromagen (both Vector Laboratories, Peterborough,
UK). Sections were then counterstained with haematoxylin
(VWR International, Leighton Buzzard, UK). For CD45+
immune cell quantiﬁcation, ﬁve non-overlapping ﬁelds from
each stained section were captured using a light microscope
(Zeiss, Germany) with identical illumination and exposure.
Digital image analysis was performed using ImageJ software.
CD45 values were expressed as the percentage of the total area
of the section occupied by CD45 staining.
Immunoﬂuorescent staining
Liver tissue was snap-frozen and cut into 7-μm-thick sections on
a cryostat. The sections were ﬁxed for 5 min in acetone.
Immunoﬂuorescent staining on cells was carried out with 100%
methanol ﬁxed primary cells grown on glass coverslips. For
human sections and primary human HSCs, the following anti-
bodies were used: monoclonal mouse IgG1 antihuman CD248
(generated in-house), monoclonal mouse IgG2a antihuman
α-SMA (Dako, Ely, UK), monoclonal mouse IgG1 antihuman
glial ﬁbrillary acidic protein (GFAP) (Dako), monoclonal mouse
IgG1 antihuman vimentin (Vector Laboratories) and monoclonal
mouse IgG1 antihuman CD90 (eBioscience). Murine sections
and primary mouse HSCs were stained with the following anti-
bodies: polyclonal rabbit antimouse CD248 (generated in-house
by Prof. Clare Isacke, Institute of Cancer Research), polyclonal
rabbit antimouse α-SMA, polyclonal goat antimouse GFAP, poly-
clonal rabbit antimouse desmin (all from Abcam), monoclonal
rat IgG2a antimouse PDGFR-α and monoclonal rat IgG2a anti-
mouse PDGFR-β (both from eBioscience) hamster antimouse
CD31 (AbD Serotec, BioRad, USA). In instances when anti-
bodies had the same isotype, sequential staining with separate
antibody incubations was carried. Species isotype (Life
Technologies, Paisley, UK) staining controls were routinely per-
formed. The primary antibodies were detected with ﬂuores-
cently conjugated secondary antibodies and in some cases
tertiary antibodies followed by DAPI as a nuclear counterstain.
Sections and cells were mounted in ﬂuorescent mountant
(Dako). The slides were visualised using a Zeiss confocal LSM
510 microscope (Zeiss) and processed using Zeiss LSM Image
Examiner software (Zeiss). Representative images are shown.
For quantitative analysis, stained sections were scanned in an
automated fashion using identical settings on an AxioScan Z1
(Zeiss) slide scanner and arithmetic mean pixel counts were ana-
lysed using Zen Lite 2012 (Zeiss).
Picrosirius red staining and quantiﬁcation
Sections were hydrated with distilled water, then placed into
0.5% phosphomolybdic for 5 min, before staining with 0.1%
Sirius red (direct red 80; % w/v in saturated picric acid) for 2 h.
The slides were dipped in 0.01 M HCl, before washing in dis-
tilled water and then mounted. To quantify Picrosirius red stain-
ing (PSR), images of ﬁve or six random ﬁelds of each section
were taken and processed with ImageJ software. Collagen values
were expressed as the percentage of the total area of the section
occupied by Sirius red staining.
Proliferation assay
Ki-67 staining was conducted for quantitative evaluation of the
HSC proliferation rate using the polyclonal rabbit anti-Ki-67
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antibody (Millipore, USA). The number of Ki-67-positive nuclei
was counted and expressed as the percentage of the total
number of nuclei to determine the frequency of Ki-67-positive
HSC.
qPCR analysis
Total RNA was extracted by Qiagen RNeasy Mini Kit (Qiagen,
California, USA) according to manufacturer’s instructions.
Complementary DNA (cDNA) was synthesised from 1 μg of RNA
using iScript cDNA Synthesis Kit (Biorad, UK). The cDNA was
then ampliﬁed by qPCR with a Lightcycler 480 using probes
(Roche, UK) and primers (Alta Biosciences, UK; see table 1). For
further mouse studies, TaqMan gene expression assays (Life
Technologies, UK) were used; CD248 (Mm00547485_s1), Tnf-α
(Mm00443258_m1), Il6 (Mm00446190_m1), Il10 (Mm004396
14_m1), Pdgfb (Mm00440677_m1), Pdgfra (Mm00440701_m1),
Pdgfrb (Mm00435546_m1), Tgfb1 (Mm01178820_m1), Ctgf
(Mm01192932_g1), Hgf (Mm01135193_m1), Timp1
(Mm00441818_m1), Mmp2 (Mm00439498_m1) and Mmp9
(Mm00442991_m1). Expression levels of the target genes were
normalised to a housekeeping gene Gapdh (Mm99999915_g1).
Gene expression values are stated as 2−ΔCt.
Western blots
Cell lysates were prepared by the addition of sodium dodecyl
sulfate (SDS) sample buffer (4% SDS (v/v), 0.1 M dithiothreitol,
20% glycerol (v/v), 0.0625 M Tris–HCl and 0.004% bromophe-
nol blue (w/v) and heated for 10 min at 100°C. Protein was
resolved on a 4–12% Novex Tris-glycine gel (Invitrogen Life
Technologies, Paisley, UK) and transferred to Hybond-N mem-
branes (GE Healthcare Life Sciences, Buckinghamshire, UK)
using a Novex X-Cell II Mini Cell. Blots were reacted with
rabbit antimouse total or phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (197G2, New England Biolabs, Herts, UK).
Detection was subsequently performed with species-speciﬁc sec-
ondary antibodies conjugated to horseradish peroxidase (GE
Healthcare Life Sciences). Protein loading was conﬁrmed by
antimouse β-actin antibody (eBioscience). Blots were visualised
by enhanced chemiluminescence (GE Healthcare Life Sciences)
and digital images and densitometry performed using a chemi-
doc Bio-Rad system. Data were expressed as relative quantiﬁca-
tion normalised to β-actin expression and presented as fold
change from unstimulated cells.
Statistical analysis
Statistical analysis was performed by Student’s t test or
Spearman’s correlation coefﬁcient using Prism software
(GraphPad, California, USA). Data are expressed as mean with
SEs. A value of p<0.05 was considered signiﬁcant.
RESULTS
Expression of hepatic CD248 increases at both the gene and
protein level during liver injury in mouse and human and
correlates with levels of ﬁbrosis
Expression levels of CD248 mRNA were higher in human cir-
rhotic end-stage liver disease (3.85-fold difference; p<0.01) as
compared with normal human liver (ﬁgure 1A). A similar
pattern was observed in chronic CCl4-induced liver ﬁbrosis in
mouse liver where CD248 expression also appeared higher
(1.6-fold difference; p=0.09) than in uninjured mouse liver
(ﬁgure 1B). Immunoﬂuorescent staining for CD248 revealed
occasional positive cells in normal human liver with a marked
increase in the number of CD248+ cells seen in cirrhotic livers
(ﬁgure 1C). CD248 was also expressed at low levels in healthy
mouse livers, whereas a considerably higher number of CD248+
cells were observed in chronically injured mouse livers (ﬁgure
1D). Having established that CD248 expression increased
during liver injury, we sought to determine which cells in the
liver were expressing CD248. Isolated HSCs from normal livers
that were activated on plastic and myoﬁbroblasts from human
cirrhotic livers expressed high levels of CD248 mRNA in con-
trast to human hepatic sinusoidal endothelial cells, biliary epi-
thelial cells and hepatocytes isolated from cirrhotic livers (ﬁgure
1E). In addition, a positive correlation was detected between
CD248 mRNA and the amount of collagen in human livers
(Spearman’s r=0.79; p<0.01; ﬁgure 1F).
CD248 is expressed on myoﬁbroblast-like cells in sinusoids
and around blood vessels in both human and mouse tissue
To further investigate the expression and localisation of CD248
in injured livers, we performed immunoﬂuorescent dual stain-
ing. CD248 expression was located in the sinusoids and around
blood vessels of cirrhotic human liver and co-localised with cells
expressing a range of myoﬁbroblast/HSC markers including
GFAP, α-SMA and vimentin (ﬁgure 2A). The distribution of
CD248+ cells was similar in CCl4-induced liver ﬁbrosis, again
being localised to the sinusoids and blood vessels. Moreover,
CD248+ cells in injured murine liver co-localised with a range
of relevant murine ﬁbroblast markers including GFAP, α-SMA
and desmin (ﬁgure 2B). To conﬁrm the identity of the cells, we
isolated quiescent human and murine HSC from normal livers
that then activated in culture and co-stained them with CD248
and HSC markers. Activated HSCs isolated from human livers
exhibited bright CD248 staining (ﬁgure 3A) as did mouse HSCs
(ﬁgure 3B). Both human and murine HSCs co-expressed
CD248 with other established stellate cell markers (ﬁgure 3).
Having established that CD248 expression is restricted to
HSCs and myoﬁbroblasts, we sought to determine the func-
tional signiﬁcance of CD248 in the generation of liver ﬁbrosis
using a CD248-deﬁcient murine model. After intraperitoneal
injection of CCl4 for 8 weeks, we veriﬁed that expression of
CD248 mRNA and protein were not increased in the liver
(ﬁgure 4A). CD248−/− mice had very low CD248 mRNA levels
compared with their WT controls (p<0.01). In addition,
minimal CD248 protein was detected in CD248−/− mice follow-
ing CCl4 injury compared with WT controls (p<0.05). In con-
trast, a signiﬁcant increase of CD248 protein expression was
detected in WT mice treated with CCl4 compared with vehicle
only (p<0.01). Following CCl4 administration, CD248
−/− mice
and WT mice both had foci of centrilobular necrosis as shown
by H&E staining (ﬁgure 4B).
CD248-deﬁcient mice have similar levels of angiogenesis
and inﬂammation following chronic CCl4-induced liver injury
Serum ALT activity was not different in CD248−/− mice com-
pared with WT mice after either 8 or 12 weeks of CCl4
Table 1 Primers used for qPCR analysis
Target Forward primer Reverse primer
Human CD248 ACCTCGGAGATGAGTTGCTG TTCCAGGCCTCGTCTTCAT
Mouse α-SMA CCGCCATGTATGTGGCTATT CAGTTGTACGTCCAGAGGCATA
Mouse Col1a1 AGACATGTTCAGCTTTGTGGAC GCAGCTGACTTCAGGGATG
Mouse c-fos CAGCCTTTCCTACTACCATTCC ACAGATCTGCGCAAAAGTCC
α-SMA, α-smooth muscle actin.
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administration (ﬁgure 4B). Also, levels of inﬂammation as
assessed by hepatic CD45 protein expression (see ﬁgure 4D and
online supplementary ﬁgure S1) and tumour necrosis factor-α,
interleukin (IL)-6 and IL-10 mRNA (ﬁgure 4E) did not vary
between CD248−/− mice and WT mice. (ﬁgure 4B). There were
no differences seen in expression of hepatic macrophages
between the two groups (see online supplementary ﬁgure S1).
Furthermore, no signiﬁcant difference was detected in levels of
angiogenesis as assessed by CD31 expression in CD248−/− mice
and WT mice treated with CCl4 for 8 weeks (ﬁgure 4C).
CD248-deﬁcient mice are protected from CCl4-induced
hepatic ﬁbrosis
To further investigate the role of CD248 in liver ﬁbrogenesis,
we examined the extent of collagen deposition and myoﬁbro-
blasts accumulation in CD248−/− and WT mice. Whereas PSR
in chronically injured WT mice revealed a signiﬁcant accumula-
tion of collagen in the portal area stretching into the lobules in
livers after 8 and 12 weeks, collagen staining in CD248−/− mice
was scarcely observed (ﬁgure 5A). Digital morphometric analysis
of PSR sections demonstrated a marked reduction in liver
Figure 1 CD248 expression is upregulated in chronic liver disease and correlates with levels of ﬁbrosis. CD248 mRNA was analysed by qPCR (A)
from normal human livers (n=12) versus end-stage diseased cirrhotic livers (n=18) and (B) livers from untreated mice (control) and mice injected
with carbon tetrachloride (CCl4) twice weekly for 8 weeks (n=6). Data represent CD248 mRNA fold changes and are shown as mean±SEM.
**p<0.01 (Student’s t test). Representative images of CD248 immunoﬂuorescent staining (red) (C) in normal and cirrhotic human liver tissue and (D)
in livers from untreated (wild-type) and CCl4 injected mice. Scale bar=50 μm. (E) RNA was isolated from primary biliary epithelial cells (BEC), hepatic
sinusoidal endothelial cells (HSEC), hepatocytes, myoﬁbroblasts and activated hepatic stellate cells (n=3 different isolates) and analysed by qPCR for
expression levels of CD248 mRNA. Results are expressed as mean±SD. (F) Normal and cirrhotic livers (n=12) were stained using Sirius red. Staining
was digitally quantiﬁed and expressed as the percentage area covered by staining of ﬁve randomly selected ﬁelds per sample. Extent of ﬁbrosis was
compared with CD248 mRNA (r=0.79; p<0.01; Spearman’s r correlation). PSR, Picrosirius red staining.
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ﬁbrosis in CD248−/− mice compared with WT mice at both 8
(56.4% reduction; p<0.0001) and 12 weeks (51.1% reduction;
p<0.05), respectively (ﬁgure 5B). To further quantify differ-
ences in ﬁbrosis, levels of procollagen α 1(I), a component of
collagen 1, and α-SMA mRNA were measured by qPCR (ﬁgure
5C, D). Procollagen α 1(I) expression was 65.3% and 64.0%
less in CD248−/− mice after 8 and 12 weeks (p<0.05) of CCl4
injury, respectively (ﬁgure 5C). Similarly, α-SMA expression
Figure 2 CD248 is expressed by stromal cells in the human and mouse liver. Representative confocal images showing localisation of CD248 (red)
to cells expressing myoﬁbroblast and hepatic stellate cell markers (green) located in blood vessels and sinusoids in (A) human chronic end-stage
liver and (B) chronically injured mouse liver sections. DAPI was used as a counterstain. Insets; zoomed images. Scale bar=50 μm. GFAP, glial
ﬁbrillary acidic protein; α-SMA, α-smooth muscle actin.
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(ﬁgure 5D) was reduced in CD248−/− mice by 62.5% and
86.1% at 8 and 12 weeks, respectively (both p<0.05).
The key ﬁbrogenic factor TGF-β is reduced in
CD248-deﬁcient mice following CCl4-induced injury
To further dissect the role of CD248 in ﬁbrosis, growth factors
involved in ﬁbrogenesis and liver injury were assessed following
CCl4 administration. Expression levels of transforming growth
factor-β (TGF-β) mRNA, which is a key pro-ﬁbrogenic growth
factor that regulates HSCs, were reduced in CD248−/− mice
compared with their WT controls (p<0.05), whereas the levels
of PDGF-BB, connective tissue growth factor and hepatocyte
growth factor mRNA did not differ (ﬁgure 6A). In addition,
mRNA expression levels of enzymes involved in matrix remod-
elling including matrix metalloproteinase (MMP)-2, MMP-9
and tissue inhibitor of metalloproteinase-1 remained unchanged
Figure 3 CD248 expression in
stromal cells in vitro from human and
mouse liver. Hepatic stellate cells
(HSCs) were isolated from normal (A)
human and (B) mouse livers and
activated on plastic. Representative
confocal images showing CD248
expression (red) in human and mouse
HSC expressing HSC markers. DAPI
was used as a counterstain. Scale
bar=50 μm. GFAP, glial ﬁbrillary acidic
protein; α-SMA, α-smooth muscle
actin.
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between CD248−/− mice and WT mice following CCl4 adminis-
tration (ﬁgure 6B). In order to exclude the possibility that deﬁ-
ciency of CD248 might have affected the abundance of HSCs,
we performed histological examination between WT and
CD248−/− mice without CCl4-induced liver injury. Livers
stained with two common markers for HSC, vimentin and
desmin, demonstrated that the number of HSCs was not
affected by genetic deletion of CD248 (ﬁgure 6C).
Deﬁciency of CD248 does not affect resolution of liver ﬁbrosis
To establish whether resolution of ﬁbrosis was altered in
CD248−/− mice, we treated WTand CD248−/− mice for 8 weeks
with CCl4 and examined their livers 4 weeks after the end of
injury. After 4 weeks resolution, WT and CD248−/− mice had
similar levels of liver ﬁbrosis (ﬁgure 7A). Levels of α-SMA and
Col1a1 mRNAwere also similar in the two groups (ﬁgure 7B, C).
CD248-deﬁcient mice are protected from hepatic ﬁbrosis
secondary to reduced HSC proliferation in response to PDGF-BB
To understand the mechanisms by which CD248 exerts its
effects on ﬁbrogenesis, we sought to establish whether PDGF,
which is a known potent HSC mitogen and which is known to
interact with CD248, played a role. Isolated HSCs from WT
and CD248−/− mice both expressed PDGFR-α mRNA and
Figure 4 CD248 knock-out does not alter inﬂammatory response to carbon tetrachloride (CCl4) injury. CD248
−/− mice and wild-type (WT) mice
were injected biweekly with CCl4 or vehicle for 8 weeks and then sacriﬁced after 2 days of the ﬁnal dose (n=6). (A) Levels of CD248 mRNA and
protein were quantiﬁed using qPCR and morphometric analysis. (B) Representative images of H&E staining of parafﬁn-embedded liver tissue sections
are shown and serum alanine aminotransferase (ALT) activity was assessed as a measure of acute liver injury. Scale bar=200 μm. (C) Digital
quantiﬁcation of CD31 expressed as the percentage area per section. (D) Digital quantiﬁcation of CD45 expressed as the percentage area of ﬁve
randomly selected areas per sample. (E) Expression levels of inﬂammatory mediators were analysed by qPCR. Data are mean±SEM. *p<0.05,
**p<0.01 (Student’s t test). GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TNF-α, tumour necrosis factor-α.
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protein at similar levels (ﬁgure 8A, B). Although PDGFR-β
mRNA was slightly lower in HSCs from CD248−/− mice,
expression levels of PDGFR-β protein did not show differences
between HSCs from WT and CD248−/− mice, indicating that
they could respond to PDGF stimulation (ﬁgure 8A, B).
Although CD248−/− HSC expressed PDGFR-α and
PDGFR-β, they did not respond to stimulation with PDGF-BB
in the same way as WT HSC. After exposure to PDGF-BB at a
dose of 10 ng/mL, WT HSCs exhibited a marked proliferative
response compared with HSCs from CD248−/− mice (ﬁgure
8C). The downstream effects of abrogated PDGF signalling in
CD248−/− HSCs were conﬁrmed by a demonstration of signiﬁ-
cantly reduced c-fos mRNA expression (0.03±0.01 vs 0.22
±0.06, p<0.05) compared with that seen in HSCs from WT
mice (ﬁgure 8D). Similarly after PDGF exposure, there was
blunted phosphorylation of ERK by CD248−/− HSCs compared
with WT HSC. As we have reported previously, baseline levels
of phospho-ERK were higher in CD248−/− HSCs (ﬁgure 8E).
Figure 5 CD248-deﬁcicient mice are protected from carbon tetrachloride (CCl4)-induced hepatic ﬁbrosis. CD248
−/− mice and wild-type (WT) mice
were injected biweekly with CCl4 for 8 or 12 weeks (n=6). (A) Liver sections were stained with Picrosirius red staining (PSR) to reveal collagen
deposition. (B) The percentage ﬁbrotic areas were assessed by ImageJ analysis of microphotographs taken of six randomly selected areas. (C) Col1a1
and (D) α-smooth muscle actin (α-SMA) gene expression analysis was performed with qPCR using total liver mRNA. Data are mean±SEM. *p<0.05,
**p<0.01, ****p<0.0001 (Student’s t test).
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DISCUSSION
In this article, we demonstrate for the ﬁrst time that CD248 is a
major regulator of liver ﬁbrosis in response to chronic injury, which
is upregulated in liver ﬁbrosis in both human and mouse settings.
We demonstrate that genetic deletion of CD248 protects against the
development of ﬁbrosis in a murine model of chronic hepatocellular
injury by interfering with PDGF signalling, and therefore represents
a novel target for therapeutic intervention in ﬁbrotic liver injury.
HSCs are considered to be the key cells that contribute to
liver ﬁbrosis.13 14 The expression of CD248 in activated HSC
Figure 6 Hepatic transforming growth factor-β (TGF-β) is reduced in CD248-deﬁcient mice following carbon tetrachloride (CCl4)-induced injury.
CD248−/− mice and wild-type (WT) mice were injected biweekly with CCl4 for 8 weeks (n=6). (A) Transcript levels of growth factors and (B) enzymes
involved in matrix remodelling were analysed by qPCR of whole liver tissue. (C) Representative images of livers from untreated CD248−/− mice and
WT mice stained with vimentin or desmin are shown. Scale bar=100 μm. CTGF, connective tissue growth factor; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; HGF, hepatocyte growth factor; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; TIMP, tissue
inhibitor of metalloproteinase.
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and myoﬁbroblasts prompted us to assess the role of CD248 in
liver ﬁbrogenesis. We showed that in an experimental model of
liver ﬁbrosis mice lacking CD248 developed less ﬁbrosis, which
may be secondary to a decrease in PDGF signal transduction
resulting in defective HSC proliferation, and hence reduced
ECM deposition. PDGF is the most potent HSC mitogen
known and is a key regulator of HSC proliferation during
hepatic ﬁbrogenesis.15 A recent study by Tomkowicz et al16 has
Figure 7 CD248 does not alter resolution of liver ﬁbrosis. CD248−/− mice and wild-type (WT) mice were injected biweekly with carbon
tetrachloride (CCl4) or vehicle for 8 weeks and then sacriﬁced either 2 days or after 4 weeks of the ﬁnal dose (resolution) (n=3–6). (A) The
percentage ﬁbrotic areas were assessed by ImageJ analysis of Picrosirius red stained (PSR) microphotographs taken of six randomly selected areas.
(B) Col1a1 and (C) α-smooth muscle actin (α-SMA) gene expression analysis was performed with qPCR using total liver mRNA. Data are mean
±SEM. *p<0.05, ***p<0.001 (Student’s t test).
Figure 8 Platelet-derived growth
factor (PDGF)-induced proliferation is
impaired in hepatic stellate cells (HSCs)
from CD248−/− mice. HSCs were
isolated from normal liver tissue from
wild-type (WT) and CD248−/− mice
and plated on plastic to initiate
activation. (A) Transcript levels of
PDGF receptor (PDGFR)-α and
PDGFR-β was analysed by qPCR (n=3).
(B) Representative images of
immunoﬂuorescent staining of HSCs
with antibodies against PDGFR-α and
PDGFR-β are shown. (C) After
stimulation with PDGF-BB, the number
of WT and CD248−/− HSCs (n=5)
proliferating was numerated by the
percentage that were Ki-67 positive.
(D) qPCR was used to analyse c-fos
expression in WT and CD248−/− HSCs
after stimulation with PDGF-BB (E)
Protein analysis by western blot for
expression of phosphorylated ERK
(P-ERK) and total ERK (T-ERK) relative
to β-actin in WT and CD248−/− HSCs
following treatment with 100 ng/mL
PDGF-BB. A representative blot is
shown with quantiﬁcation by digital
densitometry. Data are normalised to
β-actin and expressed as fold change
from unstimulated cells (n=2
independent experiments). Data are
mean±SEM. *p<0.05, **p<0.01
(Student’s t test). GAPDH,
glyceraldehyde 3-phosphate
dehydrogenase
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shown that CD248 expression is necessary for PDGF signalling
in murine pericytes. Deﬁciency of CD248 in HSCs did not alter
PDGF receptor levels, suggesting that the antiproliferative effect
of CD248−/− HSCs was not mediated through the modulation
of PDGF receptor expression. Notably our studies indicate that
PDGF signalling in CD248−/− HSCs was abrogated as demon-
strated by the signiﬁcantly reduced c-fos expression following
PDGF signalling in CD248−/− HSC.
PDGF-BB binding to PDGF receptor causes PDGF receptor
phosphorylation, which induces phosphorylation of ERK.17 The
role of CD248 is in regulating this phosphorylation of ERK,18
and thus in the absence of CD248 ERK is not phosphorylated
in response to PDGF. Phosphorylation of ERK leads to c-fos
transcription, which then mediates the downstream effects (such
as proliferation) that are used as a measure of PDGF signalling.
Indeed, it has previously been suggested that modulating the
PDGF signalling pathway could represent a strategy for guided
tissue regeneration or tissue engineering of bone.19 In this study,
we demonstrate that phosphorylation of ERK by PDGF was
blunted by the absence of CD248, but not to the same extent as
we reported with osteoblasts. Therefore, targeting of CD248
may allow selective inhibition of PDGF signalling only on acti-
vated HSCs and myoﬁbroblasts in liver injury.
Despite a decreased proliferative potential of HSCs from
CD248−/− mice, there may be other mechanisms that are
involved in reducing the levels of ﬁbrosis in CD248−/− mice.
Other investigators have reported that CD248 may reduce the
levels of inﬂammation. CD248−/− mice had signiﬁcantly less
inﬂammation than their WT controls in an arthritis model with
a decrease in leucocytes and proinﬂammatory cytokines.20
Notably we did not observe differences in inﬂammation or
angiogenesis in CD248−/− mice indicating a greater role in
ﬁbrogenesis.
The restricted expression of CD248 in HSCs and myoﬁbro-
blasts and the temporal regulation during disease makes CD248
an attractive target for the modulation of liver ﬁbrosis. Of note,
resolution of ﬁbrosis was unchanged in CD248−/− mice. In add-
ition, CD248 is expressed on the cell surface, and therefore
CD248-positive stromal cells could be a potential target for the
modulation of liver ﬁbrosis using novel antiangiogenic drugs
such as the antihuman CD248 monoclonal antibody
MORAb-004,21 currently in clinical trials in cancer.
In this study, we have identiﬁed CD248 as a novel therapeutic
target in liver ﬁbrosis. Importantly, our study demonstrates that
interfering with CD248 signalling signiﬁcantly reduces hepatic
ﬁbrosis in a mouse model of chronic liver disease. Our data
suggest that CD248 could be a new treatment target in ﬁbrotic
liver disease in humans.
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injury via a PDGF-regulated mechanism
stellate cell proliferation during chronic liver 
CD248/endosialin critically regulates hepatic
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